Published in J Clin Immunol on June 17, 2006
Biology of human cutaneous melanoma. Cancers (Basel) (2010) 0.75
Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 7.28
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Treatment of metastatic malignant melanoma. Curr Treat Options Oncol (2005) 1.49
Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol (1988) 0.95
Flow cytometric analysis of cytokine receptors on human Langerhans' cells. Changes observed after short-term culture. Immunology (1996) 0.94
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine (2005) 0.94
A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J Invest Dermatol (2001) 0.88
Dendritic cell counts in the peripheral blood of healthy adults. Am J Hematol (2005) 0.81
GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial. Oncology (Williston Park) (2005) 0.80
Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. J Immunother (2003) 0.76
Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J Sci Am (1997) 0.76
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12
Wnt5A activates the calpain-mediated cleavage of filamin A. J Invest Dermatol (2009) 1.32
Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. J Surg Res (2010) 1.04
Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma. Int J Oncol (2012) 0.88
Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm (2008) 0.86
The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg (2003) 0.85
GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial. Oncology (Williston Park) (2005) 0.80
Clinical impact of a value-based decision: a surgical case study. J Am Coll Surg (2013) 0.77
Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up. Melanoma Res (2007) 0.76
Diminished dose minimally invasive radioguided parathyroidectomy: a case for radioguidance. Am Surg (2007) 0.75
Continuous abdominal fascial closure: a randomized controlled trial of poly(L-lactide/glycolide). Gynecol Oncol (2003) 0.75
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer. Cancer Invest (2002) 0.75